Development of pneumococcal mastoiditis due to multidrug-resistant serotype 19A despite three doses of 13-valent pneumococcal vaccine

Int J Pediatr Otorhinolaryngol. 2012 Dec;76(12):1849-51. doi: 10.1016/j.ijporl.2012.08.018. Epub 2012 Sep 13.

Abstract

Acute mastoiditis is a potential complication of acute otitis media (AOM), with Streptococcus pneumoniae historically the most common pathogen isolated. Following the release of the 7-valent pneumococcal conjugate vaccine in 2000, a marked decline in invasive pneumococcal disease and a smaller reduction in pneumococcal AOM were observed, but data regarding its impact on acute mastoiditis are limited. With the recent introduction of the 13-valent pneumococcal conjugate vaccine (PCV13), it is anticipated that pneumococcal AOM and invasive disease will further diminish. We report a case of acute mastoiditis from a multidrug-resistant serotype 19A S. pneumoniae in an immunocompetent child who had received three PCV13 vaccinations.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Anti-Bacterial Agents / therapeutic use
  • Combined Modality Therapy
  • Drug Resistance, Multiple, Bacterial*
  • Female
  • Fever / diagnosis
  • Fever / etiology
  • Follow-Up Studies
  • Humans
  • Infant
  • Mastoiditis / microbiology*
  • Mastoiditis / physiopathology
  • Mastoiditis / therapy*
  • Microbial Sensitivity Tests
  • Middle Ear Ventilation / methods
  • Pneumococcal Infections / diagnosis
  • Pneumococcal Infections / prevention & control*
  • Pneumococcal Vaccines / administration & dosage*
  • Risk Assessment
  • Serotyping
  • Severity of Illness Index
  • Streptococcus pneumoniae / classification
  • Streptococcus pneumoniae / drug effects*
  • Time Factors
  • Treatment Outcome
  • Vaccines, Conjugate / administration & dosage

Substances

  • 13-valent pneumococcal vaccine
  • Anti-Bacterial Agents
  • Pneumococcal Vaccines
  • Vaccines, Conjugate